Liangpunsakul and colleagues found that aSMase inhibitors, such as imipramine, may serve as a therapeutic target for alcohol-induced hepatic steatosis by inhibiting the release of ceramides by aSMase (151). The gene discussed is SMPD1; the disease is fatty liver disease.